Stereotaxis, Inc.: insider trades · United States · SEC (Form 4)

About Stereotaxis, Inc.

Stereotaxis, Inc. (ticker: STXS) is a U.S.-listed healthcare company traded on the NYSE, headquartered in St. Louis, Missouri, United States. The company focuses on robotic systems for minimally invasive endovascular intervention, with a particular emphasis on cardiac electrophysiology and, more broadly, catheter-based vascular and neurovascular procedures. For international investors, Stereotaxis is best viewed as a specialized medtech company positioned in a high-value niche where precision navigation, reduced radiation exposure, and workflow efficiency are central value drivers. Founded more than three decades ago, Stereotaxis built its franchise around robotic magnetic navigation, a technology designed to steer catheters with high precision during complex procedures. Over time, the company has expanded from a legacy capital-equipment model toward a broader endovascular ecosystem that includes robotic platforms, cath-lab control and imaging solutions, and a growing portfolio of disposable products. Its key offerings now include GenesisX, the next-generation robotic system; the MAGiC family of robotically navigated ablation catheters; MAGiC Sweep for high-density mapping; and Synchrony, a digital cath-lab system aimed at modernizing procedure environments. In competitive terms, Stereotaxis occupies a distinctive position. It is one of the most focused players in robotic endovascular therapy, with a deep concentration in electrophysiology. That specialization gives it a differentiated clinical and technological profile versus larger diversified medtech peers, but it also means adoption depends heavily on hospital capital budgets, regulatory milestones, and physician conversion. The investment case therefore combines a niche technology leadership story with the execution risk typical of emerging medical-device platforms. Geographically, the company remains anchored in the United States, with St. Louis serving as its global headquarters, R&D, manufacturing, and distribution base. Recent developments highlight an important strategic phase. In 2025 and early 2026, Stereotaxis reported regulatory progress for GenesisX, MAGiC, MAGiC Sweep, and Synchrony, and it also announced initial U.S. clinical use of MAGiC after FDA PMA approval. In April 2026, the company disclosed a definitive agreement to acquire Robocath, a French robotics company, which should broaden its endovascular portfolio and expand its international footprint. Management also indicated double-digit revenue growth for 2026 and an expected step-up in annual revenue, while emphasizing a transition toward more recurring revenue. For equity investors, STXS offers exposure to a differentiated surgical robotics platform, with meaningful upside potential but continued sensitivity to regulatory timing, commercialization pace, and capital structure execution.